


# GSK FY 2017 results



Sales grew across all three businesses



New product sales  
**£6.7bn**

+44% CER

Adjusted Group operating margin  
**28.4%**

Total EPS  
**31.4p**


+36% CER

Adjusted EPS  
**111.8p**

+4% CER

Free cash flow  
**£3.4bn**

Dividend  
**80p**



HIV virus

See **press release** on [www.gsk.com](http://www.gsk.com) for full details on FY 2017

Please read the cautionary statement regarding **forward-looking statements** and the definitions and reconciliations for non-IFRS measures

Numbers on this slide do not add to the total because they have been rounded to the nearest £0.1bn

CER% represents growth at constant exchange rates. £% or AER% represents growth at actual exchange rates. For a full explanation please see page 39 of the press release